Hint mode is switched on Switch off
For swift navigation between sections

Intercept Pharmaceuticals
LEI 254900JMB8TX5P688V24

PDF download

Choose all Reset all
Download Cancel
Organization name
Intercept Pharmaceuticals, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

Awards

News

26/09/2023 Intercept Pharmaceuticals: Entry Into A Material Definitive Agreement, Other Events, Financial Statements And Exhibits
02/08/2023 Intercept Pharmaceuticals: Results Of Operations And Financial Condition, Financial Statements And Exhibits
22/06/2023 Intercept Pharmaceuticals: Regulation Fd Disclosure, Financial Statements And Exhibits
22/06/2023 Intercept Pharmaceuticals: Costs Associated With Exit Or Disposal Activities, Regulation Fd Disclosure, Financial Statements And Exhibits
24/05/2023 Intercept Pharmaceuticals: Submission Of Matters To A Vote Of Security Holders
All organization news

Documentation

IFRS/US GAAP reports

2023
I q eng
II q eng
III q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Latest issues

Show all

Public debt by currencies

Show more Hide

Codes

  • LEI
    254900JMB8TX5P688V24
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001270073
Registration is required to get access.